Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies

Front Neurol. 2023 Mar 16:14:1146027. doi: 10.3389/fneur.2023.1146027. eCollection 2023.

Authors

Joseph R Berger¹, Hans-Peter Hartung^{2

3

4}

Affiliations

¹ Department of Neurology, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, United States.
² Department of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
³ Brain and Mind Center, University of Sydney, Sydney, NSW, Australia.
⁴ Department of Neurology, Palacky University, Olomouc, Czechia.

No abstract available

Keywords: immunogenetics; multiple sclerosis; natalizumab; progressive multifocal leucoencephalopathy (PML); risk factors.

Publication types

Comment